By Stephen Nakrosis 
 

Bristol-Myers Squibb Co. (BMY) and bluebird bio Inc. (BLUE) said results from a Phase 2 study of their idecabtagene vicleucel treatment for certain myeloma patients met its primary endpoint and key secondary endpoint.

Idecabtagene vicleucel, or ide-cel, is an investigational treatment for certain patients with relapsed and refractory multiple myeloma, the companies said.

The KarMMa Phase 2 study "met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population," the companies said.

The companies said they are "are actively preparing for submission of these data to health authorities for proposed initial registration of ide-cel as a first-in-class BCMA-targeted CAR T cell therapy."

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 06, 2019 17:15 ET (22:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bluebird Bio (NASDAQ:BLUE)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Bluebird Bio Charts.
Bluebird Bio (NASDAQ:BLUE)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Bluebird Bio Charts.